The "Cancer Antibody Drug Conjugates Global Market Report 2025" has been added to ResearchAndMarkets.com's offering.The ...
The Phase II segment is a randomised, double-blind, placebo-controlled study assessing ABCL635 efficacy in 80 postmenopausal ...
AbCellera Biologics (NASDAQ:ABCL) used its presentation at the 2026 JPMorgan Healthcare Conference to outline its shift from ...
Cedar fever is a seasonal allergy common in Central Texas. It happens when the male mountain ashe juniper trees get frisky ...
Scientists have identified a promising target for treatment of a devastating autoimmune disease affecting the brain.
In a Jan. 13th installation of the Stanford Cancer Institute’s “Breakthroughs in Cancer” lecture series, Lawrence Fong M.D.’92 discussed his lab’s research enhancing internal immune responses in ...
Spanish dermatology specialist Almirall (BME: ALM) is using its appearance at the 44th JP Morgan Healthcare Conference in San ...
The J.P. Morgan Healthcare Conference, as well as Fierce's own JPM Week, roll into Wednesday with plenty more events, ...
AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving ...
Robert F. Kennedy, Jr.’s Centers for Disease Control and Prevention has slashed childhood vaccine recommendations in the ...
Set for multiple late-stage readouts in oncology in 2026, BioNTech is entering a crucial phase of its roadmap beyond Covid-19 ...
The bispecific antibody—which targets the IL-23p19 and TL1A pathways—was licensed from China’s Qyuns Therapeutics. Since being founded last year, Caldera has already taken the therapy, dubbed CLD-423, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback